CONFERENCE COVERAGE
American College of Rheumatology
Annual Meeting
2019 COVERAGE
- Ixekizumab Superior to Adalimumab in Joint, Skin Improvement in PsA
- Improved Axial Manifestations With Secukinumab in PsA Not Responsive to NSAIDs
- Improvement in Symptoms, Inflammation in Nonradiographic axSpA With Ixekizumab
- Etanercept Shows Sustained Clinical Response Over 10 Years in axSpA
- Disease Activity, Functional Impairment in axSpA With Psoriasis or IBD
- TNFα, IL-12/23 Blockage May Improve Depressive Symptoms in PsA
- ASDAS vs BASDAI: Predicting Biologic Treatment Response in axSpA With Coexistent Fibromyalgia
- Secukinumab Improves Nail Psoriasis, Radiographic Progression Inhibition in PsA
- Higher Rates of Treated Depression With Corticosteroids, Interleukin Inhibitors in PsA
- TNF Inhibitors Reduce Radiographic Progression in AS
- Clinical Risk Factors Similar Across Rheumatic Diseases
- Opioids Offer Only Minor Pain Relief in OA
Latest Tweets
Follow
@RheumAdvisor
Conference Coverage from
